Translating preclinical myeloid biology into clinical trials

Intervista a Thomas Marron By 3 Dicembre 2025No Comments
Dai congressi

How to translate preclinical myeloid biology into potential new targets for Immunotherapy? We asked Thomas Marron (Director of the Early Phase Trials Unit – EPTU at The Tisch Cancer Institute, Professor of Hematology and Medical Oncology and Professor of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai Hospital, New York), that we met at Immunotherapy Bridge 2025 congress in Naples.